Recent insights into the HIV/AIDS pandemic

Microbial Cell

Volumn 3, Issue 9, 2016, Pages 451-475

  Becerra, Juan C ^a   Bildstein, Lukas S ^b   Gach, Johannes S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Graphic Design   (Austria)

Author keywords

AIDS; Antiretroviral therapy; Epidemiology; HIV 1; Pathology; Treatment; Virus entry

Indexed keywords

EID: 85032818556     PISSN: None     EISSN: 23112638     Source Type: Journal    
DOI: 10.15698/mic2016.09.529     Document Type: Review

References (288)

1. Sharp PM, Hahn BH (2011). Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 1(1): a006841.
2. Hymes KB, Cheung T, Greene JB, Prose NS, Marcus A, Ballard H, William DC, Laubenstein LJ (1981). Kaposi's sarcoma in homosexual men-a report of eight cases. Lancet 2(8247): 598-600.
3. Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA, Holzman RS, Wormser G, Brettman L, Lange M, Murray HW, Cunningham-Rundles S (1981). An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 305(24): 1431-1438.
4. Broder S, Gallo RC (1984). A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med 311(20): 1292-1297.
5. Piot P, Quinn TC, Taelman H, Feinsod FM, Minlangu KB, Wobin O, Mbendi N, Mazebo P, Ndangi K, Stevens W, et al. (1984). Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet 2(8394): 65-69.
6. Van de Perre P, Rouvroy D, Lepage P, Bogaerts J, Kestelyn P, Kayihigi J, Hekker AC, Butzler JP, Clumeck N (1984). Acquired immunodeficiency syndrome in Rwanda. Lancet 2(8394): 62-65.
7. Hahn BH, Shaw GM, De Cock KM, Sharp PM (2000). AIDS as a zoonosis: scientific and public health implications. Science 287(5453): 607-614.
8. Faria NR, Rambaut A, Suchard MA, Baele G, Bedford T, Ward MJ, Tatem AJ, Sousa JD, Arinaminpathy N, Pepin J, Posada D, Peeters M, Pybus OG, Lemey P (2014). HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations. Science 346(6205): 56-61.
9. Mourez T, Simon F, Plantier JC (2013). Non-M variants of human immunodeficiency virus type 1. Clin Microbiol Rev 26(3): 448-461.
10. Peeters M, D'Arc M, Delaporte E (2014). Origin and diversity of human retroviruses. AIDS Rev 16(1): 23-34.
11. Lloyd SB, Kent SJ, Winnall WR (2014). The high cost of fidelity. AIDS Res Hum Retroviruses 30(1): 8-16.
12. Li WH, Tanimura M, Sharp PM (1988). Rates and dates of divergence between AIDS virus nucleotide sequences. Mol Biol Evol 5(4): 313-330.
13. Smith DM, Richman DD, Little SJ (2005). HIV superinfection. J Infect Dis 192(3): 438-444.
14. Simon V, Ho DD, Abdool Karim Q (2006). HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368(9534): 489-504.
15. UNAIDS (2015). AIDS by the numbers. Available at: http://www.unaids.org/en/resources/documents/2015/AIDS_by_the_ numbers_2015 [Accessed 15.12.2015].
16. Shisana O RT, Simbayi LC, Zuma K, Jooste S, Zungu N, Labadarios D, Onoya D et al. (2014). South African National HIV Prevalence, Incidence and Behaviour Survey, 2012. Cape Town: HSRC Press
17. WHO (2015). HIV/AIDS. Available at: http://www.who.int/hiv/data/epi_core_july2015.png [Accessed 15.12.2015].
18. UNAIDS (2014). The Gap report. Available at: http://www.unaids.org/en/resources/documents/2014/20140716_U NAIDS_gap_report [Accessed 18.12.2015].
19. Karim QA, Kharsany AB, Frohlich JA, Werner L, Mashego M, Mlotshwa M, Madlala BT, Ntombela F, Abdool Karim SS (2011). Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol 40(4): 922-930.
20. Dellar RC, Dlamini S, Karim QA (2015). Adolescent girls and young women: key populations for HIV epidemic control. J Int AIDS Soc 18(2 Suppl 1): 19408.
21. Bekker LG, Johnson L, Wallace M, Hosek S (2015). Building our youth for the future. J Int AIDS Soc 18(2 Suppl 1): 20027.
22. UNAIDS (2013). HIV in Asia and the Pacific. Available at: http://www.unaids.org/en/resources/documents/2013/20131119_HI V-Asia-Pacific [Accessed 18.12.2015].
23. Cowell A, Shenoi SV, Kyriakides TC, Friedland G, Barakat LA (2015). Trends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy era, 1995 to 2011. J Hosp Med 10(9): 608-614.
24. Triant VA (2013). Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep 10(3): 199-206.
25. Saravanan S, Velu V, Kumarasamy N, Nandakumar S, Murugavel KG, Balakrishnan P, Suniti S, Thyagarajan SP (2007). Coinfection of hepatitis B and hepatitis C virus in HIV-infected patients in south India. World J Gastroenterol 13(37): 5015-5020. doi.
26. Khalsa JH, Elkashef A (2010). Interventions for HIV and hepatitis C virus infections in recreational drug users. Clin Infect Dis 50(11): 1505-1511.
27. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S (2005). How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 191(2): 150-158.
28. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, Zheng H, Lu Z, Freedberg KA, Losina E (2006). CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 42(4): 464-469.
29. UNAIDS (2015). Fact Sheet. Available at: http://www.unaids.org/en/resources/campaigns/HowAIDSchangedev erything/factsheet [Accessed 22.12.2015].
30. Chiu IM, Yaniv A, Dahlberg JE, Gazit A, Skuntz SF, Tronick SR, Aaronson SA (1985). Nucleotide sequence evidence for relationship of AIDS retrovirus to lentiviruses. Nature 317(6035): 366-368.
31. Hutchinson JF (2001). The biology and evolution of HIV. Annual Review of Anthropology 30: 85-108.
32. Freed EO (2001). HIV-1 replication. Somat Cell Mol Genet 26(1-6): 13-33.
33. Jablonski JA, Amelio AL, Giacca M, Caputi M (2010). The transcriptional transactivator Tat selectively regulates viral splicing. Nucleic Acids Res 38(4): 1249-1260.
34. Cimarelli A, Darlix JL (2014). HIV-1 reverse transcription. Methods Mol Biol 1087(55-70.
35. Chamanian M, Purzycka KJ, Wille PT, Ha JS, McDonald D, Gao Y, Le Grice SF, Arts EJ (2013). A cis-acting element in retroviral genomic RNA links Gag-Pol ribosomal frameshifting to selective viral RNA encapsidation. Cell Host Microbe 13(2): 181-192.
36. Coffin JM, Hughes SH, Varmus HE (1997). The Interactions of Retroviruses and their Hosts. In: Coffin JM, Hughes SH, Varmus HE, editors. Retroviruses. Cold Spring Harbor (NY).
37. Craigie R, Bushman FD (2012). HIV DNA integration. Cold Spring Harb Perspect Med 2(7): a006890.
38. Hewson T, Lone N, Moore M, Howie S (1999). Interactions of HIV-1 with antigen-presenting cells. Immunol Cell Biol 77(4): 289-303.
39. Swanstrom R, Coffin J (2012). HIV-1 pathogenesis: the virus. Cold Spring Harb Perspect Med 2(12): a007443.
40. Campo J, Perea MA, del Romero J, Cano J, Hernando V, Bascones A (2006). Oral transmission of HIV, reality or fiction? An update. Oral Dis 12(3): 219-228.
41. Petroll AE, Hare CB, Pinkerton SD (2008). The essentials of HIV: a review for nurses. J Infus Nurs 31(4): 228-235.
42. Morison L (2001). The global epidemiology of HIV/AIDS. Br Med Bull 58: 7-18.
43. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J (2014). Estimating per-act HIV transmission risk: a systematic review. AIDS 28(10): 1509-1519.
44. Grulich AE, Zablotska I (2010). Commentary: probability of HIV transmission through anal intercourse. Int J Epidemiol 39(4): 1064-1065.
45. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M (2009). Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 9(2): 118-129.
46. Keele BF, Estes JD (2011). Barriers to mucosal transmission of immunodeficiency viruses. Blood 118(4): 839-846.
47. Shacklett B (2014). Mucosal Immunity to HIV-1. Encyclopedia of AIDS.
48. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH (2000). Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342(13): 921-929.
49. Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, Mugo NR, Wald A, Corey L, Donnell D, Campbell MS, Mullins JI, Celum C, Partners in Prevention HSVHIVTST (2011). Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 3(77): 77ra29.
50. Ribeiro RM, Qin L, Chavez LL, Li D, Self SG, Perelson AS (2010). Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol 84(12): 6096-6102.
51. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, Kiarie J, Inambao M, Kilembe W, Farquhar C, Celum C, Partners in Prevention HSVHIVTST (2012). Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 205(3): 358-365.
52. Cohen MS (2007). Preventing sexual transmission of HIV. Clin Infect Dis 45 Suppl 4: S287-292.
53. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, Nalugoda F, Wabwire-Mangen F, Meehan MP, Quinn TC (2005). Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191(9): 1403-1409.
54. Galvin SR, Cohen MS (2004). The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2(1): 33-42.
55. Machado JR, da Silva MV, Cavellani CL, dos Reis MA, Monteiro MLGD, Teixeira VDA, Correa RR (2014). Mucosal Immunity in the Female Genital Tract, HIV/AIDS. Biomed Research International.
56. Sheffield JS, Wendel GD, Jr., McIntire DD, Norgard MV (2007). Effect of genital ulcer disease on HIV-1 coreceptor expression in the female genital tract. J Infect Dis 196(10): 1509-1516.
57. Marrazzo JM, Thomas KK, Ringwood K (2011). A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sex Transm Infect 87(5): 399-405.
58. Mirmonsef P, Krass L, Landay A, Spear GT (2012). The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr HIV Res 10(3): 202-210.
59. Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Daly CC, Zimba D, Vernazza PL, Maida M, Fiscus SA, Eron JJ, Jr. (1997). Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 349(9069): 1868-1873.
60. Shafir SC, Sorvillo FJ, Smith L (2009). Current issues and considerations regarding trichomoniasis and human immunodeficiency virus in African-Americans. Clin Microbiol Rev 22(1): 37-45, Table of Contents.
61. Lama J, Planelles V (2007). Host factors influencing susceptibility to HIV infection and AIDS progression. Retrovirology 4: 52.
62. Ramjee G, Daniels B (2013). Women and HIV in Sub-Saharan Africa. AIDS Res Ther 10(1): 30.
63. Hirbod T, Kong X, Kigozi G, Ndyanabo A, Serwadda D, Prodger JL, Tobian AA, Nalugoda F, Wawer MJ, Shahabi K, Rojas OL, Gommerman JL, Broliden K, Kaul R, Gray RH (2014). HIV acquisition is associated with increased antimicrobial peptides and reduced HIV neutralizing IgA in the foreskin prepuce of uncircumcised men. PLoS Pathog 10(10): e1004416.
64. Leclerc PM, Dubois-Colas N, Garenne M (2008). Hormonal contraception and HIV prevalence in four African countries. Contraception 77(5): 371-376.
65. Watson-Jones D, Baisley K, Weiss HA, Tanton C, Changalucha J, Everett D, Chirwa T, Ross D, Clayton T, Hayes R (2009). Risk factors for HIV incidence in women participating in an HSV suppressive treatment trial in Tanzania. AIDS 23(3): 415-422.
66. Hel Z, Stringer E, Mestecky J (2010). Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 31(1): 79-97.
67. Wilkinson D, Ramjee G, Tholandi M, Rutherford G (2002). Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men. Cochrane Database Syst Rev 4): CD003936.
68. Wilkinson D, Tholandi M, Ramjee G, Rutherford GW (2002). Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2(10): 613-617.
69. Laga M, Piot P (2012). Prevention of sexual transmission of HIV: real results, science progressing, societies remaining behind. AIDS 26(10): 1223-1229.
70. Marrazzo JM, Cates W (2011). Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis 53 Suppl 3: S64-78.
71. Chang LW, Serwadda D, Quinn TC, Wawer MJ, Gray RH, Reynolds SJ (2013). Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. Lancet Infect Dis 13(1): 65-76.
72. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, et al. (2011). Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365(6): 493-505.
73. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML (2013). High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 339(6122): 966-971.
74. Mutevedzi PC (2014). The changing face of the HIV epidemic in sub-Saharan Africa (vol 19, pg 1015, 2014). Tropical Medicine & International Health 19(12): 1525-1525.
75. Jean K, Gabillard D, Moh R, Danel C, Fassassi R, Desgrees-du-Lou A, Eholie S, Lert F, Anglaret X, Dray-Spira R (2014). Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk among adults with diverse heterosexual partnership statuses in Cote d'Ivoire. J Infect Dis 209(3): 431-440.
76. Labhardt ND, Motlomelo M, Cerutti B, Pfeiffer K, Kamele M, Hobbins MA, Ehmer J (2014). Home-based versus mobile clinic HIV testing and counseling in rural Lesotho: a cluster-randomized trial. PLoS Med 11(12): e1001768.
77. Suthar AB, Ford N, Bachanas PJ, Wong VJ, Rajan JS, Saltzman AK, Ajose O, Fakoya AO, Granich RM, Negussie EK, Baggaley RC (2013). Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med 10(8): e1001496.
78. Sharma M, Ying R, Tarr G, Barnabas R (2015). Systematic review and meta-analysis of community and facility-based HIV testing to address linkage to care gaps in sub-Saharan Africa. Nature 528(7580): S77-85.
79. Nichols BE, Boucher CA, van de Vijver DA (2011). HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance. J Intern Med 270(6): 532-549.
80. Tully S, Cojocaru M, Bauch CT (2015). Sexual behavior, risk perception, and HIV transmission can respond to HIV antiviral drugs and vaccines through multiple pathways. Sci Rep 5: 15411.
81. Medley A, Garcia-Moreno C, McGill S, Maman S (2004). Rates, barriers and outcomes of HIV serostatus disclosure among women in developing countries: implications for prevention of mother-to-child transmission programmes. Bull World Health Organ 82(4): 299-307.
82. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernandez T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallas EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, et al. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363(27): 2587-2599.
83. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT, Group TDFS (2012). Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367(5): 423-434.
84. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, Chuachoowong R, Gvetadze RJ, McNicholl JM, Paxton LA, Curlin ME, Hendrix CW, Vanichseni S, Bangkok Tenofovir Study G (2013). Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381(9883): 2083-2090.
85. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, et al. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367(5): 399-410.
86. Molina JM, Pintado C, Gatey C, Ponscarme D, Charbonneau P, Loze B, Rozenbaum W, Delaugerre C (2013). Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe? BMC Med 11: 186.
87. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Preau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Dore V, et al. (2015). On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med 373(23): 2237-2246.
88. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-Mangen F, Bacon MC, Williams CF, Opendi P, Reynolds SJ, Laeyendecker O, Quinn TC, Wawer MJ (2007). Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369(9562): 657-666.
89. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO (2007). Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369(9562): 643-656.
90. Wamai RG, Morris BJ, Bailis SA, Sokal D, Klausner JD, Appleton R, Sewankambo N, Cooper DA, Bongaarts J, de Bruyn G, Wodak AD, Banerjee J (2011). Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. J Int AIDS Soc 14: 49.
91. Tobian AA, Kacker S, Quinn TC (2014). Male circumcision: a globally relevant but under-utilized method for the prevention of HIV and other sexually transmitted infections. Annu Rev Med 65: 293-306.
92. Dobard C, Sharma S, Martin A, Pau CP, Holder A, Kuklenyik Z, Lipscomb J, Hanson DL, Smith J, Novembre FJ, Garcia-Lerma JG, Heneine W (2012). Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol 86(2): 718-725.
93. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, Group CT (2010). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996): 1168-1174.
94. Dobard CW, Sharma S, Cong ME, West R, Makarova N, Holder A, Pau CP, Hanson DL, Novembre FJ, Garcia-Lerma JG, Heneine W (2015). Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques. Retrovirology 12: 69.
95. Rees H D-MS, Baron D, Lombard C, Gray G, Myer L, Panchia R, Schwartz J, Doncel G (2015). FACTS 001 Phase III trial of pericoital tenofovir 1% gel for HIV prevention in women [abstract 26LB] Program and abstracts of the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) CROI, Seattle.
96. Mayer KH (2016). NextGen HIV prevention: new possibilities and questions. Lancet 387(10023): 1036-1038.
97. Devlin B, Nuttall J, Wilder S, Woodsong C, Rosenberg Z (2013). Development of dapivirine vaginal ring for HIV prevention. Antiviral Res 100 Suppl: S3-8.
98. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Matovu Kiweewa F, Nair G, Mhlanga F, Siva S, Bekker LG, Jeenarain N, Gaffoor Z, Martinson F, Makanani B, Pather A, Naidoo L, Husnik M, Richardson BA, Parikh UM, Mellors JW, Marzinke MA, Hendrix CW, van der Straten A, Ramjee G, Chirenje ZM, Nakabiito C, Taha TE, Jones J, et al. (2016). Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med.
99. Maartens G, Celum C, Lewin SR (2014). HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384(9939): 258-271.
100. Barnabas RV, Celum C (2012). Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res 10(3): 228-237.
101. Buchanan AM, Cunningham CK (2009). Advances and failures in preventing perinatal human immunodeficiency virus infection. Clin Microbiol Rev 22(3): 493-507.
102. Newell ML (2001). Prevention of mother-to-child transmission of HIV: challenges for the current decade. Bull World Health Organ 79(12): 1138-1144.
103. Chasela C, Chen YQ, Fiscus S, Hoffman I, Young A, Valentine M, Emel L, Taha TE, Goldenberg RL, Read JS (2008). Risk factors for late postnatal transmission of human immunodeficiency virus type 1 in sub-Saharan Africa. Pediatr Infect Dis J 27(3): 251-256.
104. Breastfeeding, Group HIVITS, Coutsoudis A, Dabis F, Fawzi W, Gaillard P, Haverkamp G, Harris DR, Jackson JB, Leroy V, Meda N, Msellati P, Newell ML, Nsuati R, Read JS, Wiktor S (2004). Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 189(12): 2154-2166.
105. Coovadia HM, Rollins NC, Bland RM, Little K, Coutsoudis A, Bennish ML, Newell ML (2007). Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 369(9567): 1107-1116.
106. John-Stewart G, Mbori-Ngacha D, Ekpini R, Janoff EN, Nkengasong J, Read JS, Van de Perre P, Newell ML, Ghent IASWGoHIViWC (2004). Breast-feeding and Transmission of HIV-1. J Acquir Immune Defic Syndr 35(2): 196-202.
107. Dunn DT, Newell ML, Ades AE, Peckham CS (1992). Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 340(8819): 585-588.
108. Townsend CL, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H, Taylor GP, Peckham CS, Tookey PA (2014). Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS 28(7): 1049-1057.
109. John GC, Nduati RW, Mbori-Ngacha DA, Richardson BA, Panteleeff D, Mwatha A, Overbaugh J, Bwayo J, Ndinya-Achola JO, Kreiss JK (2001). Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 183(2): 206-212.
110. Fowler MG, Kourtis AP, Aizire J, Onyango-Makumbi C, Bulterys M (2012). Breastfeeding and transmission of HIV-1: epidemiology and global magnitude. Adv Exp Med Biol 743: 3-25.
111. Drake AL, Wagner A, Richardson B, John-Stewart G (2014). Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med 11(2): e1001608.
112. Meintjes G, Maartens G, Boulle A, Conradie F, Goemaere E, Hefer E, Johnson D, Mathe M, Moosa Y, Osih R, Rossouw T, van Cutsem G, Variava E, Venter F, Spencer D, Clinicians SAH (2012). Guidelines for antiretroviral therapy in adults. Southern African Journal of Hiv Medicine 45.
113. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB, et al. (2013). Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369(22): 2083-2092.
114. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp HIVVSG (2005). Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191(5): 654-665.
115. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K, Bangkok Vaccine Evaluation G (2006). Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194(12): 1661-1671.
116. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN, Step Study Protocol T (2008). Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653): 1881-1893.
117. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR, Step Study Protocol T (2008). HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372(9653): 1894-1905.
118. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG, team HPs (2011). Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 11(7): 507-515.
119. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, et al. (2012). Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366(14): 1275-1286.
120. Vaccari M, Poonam P, Franchini G (2010). Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev Vaccines 9(9): 997-1005.
121. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, Investigators M-T (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361(23): 2209-2220.
122. Xu H, Wang X, Veazey RS (2013). Mucosal immunology of HIV infection. Immunol Rev 254(1): 10-33.
123. Shattock RJ, Haynes BF, Pulendran B, Flores J, Esparza J, Working Group convened by the Global HIVVE (2008). Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med 5(4): e81.
124. Akira S, Uematsu S, Takeuchi O (2006). Pathogen recognition and innate immunity. Cell 124(4): 783-801.
125. Saksena NK, Wang B, Zhou L, Soedjono M, Ho YS, Conceicao V (2010). HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. HIV AIDS (Auckl) 2(103-122.
126. Chen P, Chen BK, Mosoian A, Hays T, Ross MJ, Klotman PE, Klotman ME (2011). Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells. J Am Soc Nephrol 22(3): 496-507.
127. Miller CJ, Shattock RJ (2003). Target cells in vaginal HIV transmission. Microbes Infect 5(1): 59-67.
128. Gupta S, Gach JS, Becerra JC, Phan TB, Pudney J, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ, Ping LH, Corti D, Moldt B, Hel Z, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ, Forthal DN (2013). The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog 9(11): e1003776.
129. Pope M, Haase AT (2003). Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 9(7): 847-852.
130. Lackner AA, Veazey RS (2007). Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med 58(461-476.
131. Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, Lee FH, Didigu CA, Berro R, Klasse PJ, Lee B, Moore JP, Shaw GM, Hahn BH, Doms RW (2013). Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol 87(5): 2401-2411.
132. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, et al. (2008). Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105(21): 7552-7557.
133. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP, Jr., Bjorkman PJ, Wilen CB, Doms RW, O'Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, et al. (2013). Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A 110(17): 6626-6633.
134. Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferott K, Aasa-Chapman MM, Pellegrino P, Williams I, Cohen MS, Gao F, Shaw GM, Hahn BH, Ochsenbauer C, Kappes JC, Borrow P (2013). Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 10: 146.
135. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, Salazar-Gonzalez JF, Shattock R, Haynes BF, Shaw GM, Hahn BH, Kappes JC (2012). Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 86(5): 2715-2728.
136. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB, Bar KJ, Davis KL, Ochsenbauer-Jambor C, Kappes JC, Saag MS, Cohen MS, Mulenga J, Derdeyn CA, Allen S, Hunter E, Markowitz M, Hraber P, Perelson AS, Bhattacharya T, Haynes BF, Korber BT, Hahn BH, et al. (2009). Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206(6): 1273-1289.
137. Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, Hunter E (2010). Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry. J Virol 84(8): 4100-4104.
138. Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S, Hunter E, Derdeyn CA, Collman RG (2009). Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol 83(16): 8208-8220.
139. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E (2004). Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303(5666): 2019-2022.
140. Zhang H, Rola M, West JT, Tully DC, Kubis P, He J, Kankasa C, Wood C (2010). Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. Virology 400(2): 164-174.
141. Nawaz F, Cicala C, Van Ryk D, Block KE, Jelicic K, McNally JP, Ogundare O, Pascuccio M, Patel N, Wei D, Fauci AS, Arthos J (2011). The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog 7(2): e1001301.
142. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J (2005). Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 79(10): 6528-6531.
143. Liu Y, Curlin ME, Diem K, Zhao H, Ghosh AK, Zhu H, Woodward AS, Maenza J, Stevens CE, Stekler J, Collier AC, Genowati I, Deng W, Zioni R, Corey L, Zhu T, Mullins JI (2008). Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses. Virology 374(2): 229-233.
144. Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Petersen JE, Wojcechowskyj JA, Sodroski J, Haynes BF, Montefiori DC, Tilton JC, Shaw GM, Hahn BH, Doms RW (2011). Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol 85(17): 8514-8527.
145. Coffin J, Swanstrom R (2013). HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harb Perspect Med 3(1): a012526.
146. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, Self SG, Borrow P (2009). Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 83(8): 3719-3733.
147. Pincus JM, Crosby SS, Losina E, King ER, LaBelle C, Freedberg KA (2003). Acute human immunodeficiency virus infection in patients presenting to an urban urgent care center. Clin Infect Dis 37(12): 1699-1704.
148. Picker LJ, Hansen SG, Lifson JD (2012). New paradigms for HIV/AIDS vaccine development. Annu Rev Med 63: 95-111.
149. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, Keele BF, Learn GH, Turnbull EL, Salazar MG, Weinhold KJ, Moore S, B CCC, Letvin N, Haynes BF, Cohen MS, Hraber P, Bhattacharya T, Borrow P, Perelson AS, Hahn BH, Shaw GM, Korber BT, McMichael AJ (2009). The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 206(6): 1253-1272.
150. Althaus CL, De Boer RJ (2008). Dynamics of Immune Escape during HIV/SIV Infection. Plos Computational Biology 4(7).
151. Ladell K, Hashimoto M, Iglesias MC, Wilmann PG, McLaren JE, Gras S, Chikata T, Kuse N, Fastenackels S, Gostick E, Bridgeman JS, Venturi V, Arkoub ZA, Agut H, van Bockel DJ, Almeida JR, Douek DC, Meyer L, Venet A, Takiguchi M, Rossjohn J, Price DA, Appay V (2013). A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. Immunity 38(3): 425-436.
152. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, Burgett N, Swartz ME, Yang A, Alter G, Yu XG, Meier A, Rockstroh JK, Allen TM, Jessen H, Rosenberg ES, Carrington M, Walker BD (2006). HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med 3(10): e403.
153. Scherer A, Frater J, Oxenius A, Agudelo J, Price DA, Gunthard HF, Barnardo M, Perrin L, Hirschel B, Phillips RE, McLean AR, Swiss HIVCS (2004). Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. Proc Natl Acad Sci U S A 101(33): 12266-12270.
154. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, Tang Y, Holmes EC, Allen T, Prado JG, Altfeld M, Brander C, Dixon C, Ramduth D, Jeena P, Thomas SA, St John A, Roach TA, Kupfer B, Luzzi G, Edwards A, Taylor G, Lyall H, Tudor-Williams G, Novelli V, Martinez-Picado J, Kiepiela P, Walker BD, Goulder PJ (2004). HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10(3): 282-289.
155. Brennan CA, Ibarrondo FJ, Sugar CA, Hausner MA, Shih R, Ng HL, Detels R, Margolick JB, Rinaldo CR, Phair J, Jacobson LP, Yang OO, Jamieson BD (2012). Early HLA-B*57-restricted CD8+ T lymphocyte responses predict HIV-1 disease progression. J Virol 86(19): 10505-10516.
156. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, Routy JP, Haddad EK, Sekaly RP (2006). Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12(10): 1198-1202.
157. Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, Koelle DM, McElrath MJ, Horton H (2011). Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med 17(8): 989-995.
158. Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, Soma T, Bean AT, Beal DR, Wilson NA, Rehrauer WM, Lifson JD, Carrington M, Watkins DI (2007). Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol 81(16): 8827-8832.
159. Yant LJ, Friedrich TC, Johnson RC, May GE, Maness NJ, Enz AM, Lifson JD, O'Connor DH, Carrington M, Watkins DI (2006). The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 80(10): 5074-5077.
160. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF (2010). The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10(1): 11-23.
161. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100(7): 4144-4149.
162. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Pena AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M (2014). Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515(7525): 138-142.
163. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC (2009). Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83(14): 7337-7348.
164. Kwong PD, Mascola JR (2012). Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37(3): 412-425.
165. Aziz M, Mahmood F, Mata M, Durkin HG, Liu C, Greenblatt RM, Nowicki M, Golub ET, Anastos K, French AL, Baum LL (2015). Development of IgG Mediated Antibody Dependent Cell-mediated Cytotoxicity (ADCC) in the Serum and Genital Mucosa of HIV Seroconverters. J AIDS Clin Res 6(7).
166. Su B, Moog C (2014). Which Antibody Functions are Important for an HIV Vaccine? Front Immunol 5(289).
167. Williams KL, Cortez V, Dingens AS, Gach JS, Rainwater S, Weis JF, Chen X, Spearman P, Forthal DN, Overbaugh J (2015). HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and are Commonly Detected in Plasma from HIV-infected Humans. EBioMedicine 2(10): 1464-1477.
168. Forthal DN, Landucci G, Chohan B, Richardson BA, McClelland RS, Jaoko W, Blish C, Overbaugh J (2013). Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection. J Acquir Immune Defic Syndr 63(1): 31-33.
169. Gach JS, Achenbach CJ, Chromikova V, Berzins B, Lambert N, Landucci G, Forthal DN, Katlama C, Jung BH, Murphy RL (2014). HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One 9(1): e85371.
170. Sips M, Krykbaeva M, Diefenbach TJ, Ghebremichael M, Bowman BA, Dugast AS, Boesch AW, Streeck H, Kwon DS, Ackerman ME, Suscovich TJ, Brouckaert P, Schacker TW, Alter G (2016). Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies. Mucosal Immunol.
171. Mascola JR, Montefiori DC (2010). The role of antibodies in HIV vaccines. Annu Rev Immunol 28(413-444.
172. Nabel GJ, Kwong PD, Mascola JR (2011). Progress in the rational design of an AIDS vaccine. Philos Trans R Soc Lond B Biol Sci 366(1579): 2759-2765.
173. Kwong PD, Mascola JR, Nabel GJ (2011). Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med 1(1): a007278.
174. Jung AC, Paauw DS (1998). Diagnosing HIV-related disease: using the CD4 count as a guide. J Gen Intern Med 13(2): 131-136.
175. Tokman S, Huang L (2013). Evaluation of respiratory disease. Clin Chest Med 34(2): 191-204.
176. Janoff EN, Breiman RF, Daley CL, Hopewell PC (1992). Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 117(4): 314-324.
177. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, Markowitz N, Rosen MJ, Mangura BT, Hopewell PC (1995). Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 333(13): 845-851.
178. Lackner AA, Lederman MM, Rodriguez B (2012). HIV pathogenesis: the host. Cold Spring Harb Perspect Med 2(9): a007005.
179. Langford SE, Ananworanich J, Cooper DA (2007). Predictors of disease progression in HIV infection: a review. AIDS Res Ther 4(11.
180. Liovat AS, Rey-Cuille MA, Lecuroux C, Jacquelin B, Girault I, Petitjean G, Zitoun Y, Venet A, Barre-Sinoussi F, Lebon P, Meyer L, Sinet M, Muller-Trutwin M (2012). Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One 7(10): e46143.
181. Paiardini M, Muller-Trutwin M (2013). HIV-associated chronic immune activation. Immunol Rev 254(1): 78-101.
182. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA (2003). Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101(7): 2711-2720.
183. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD (2006). PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109): 350-354.
184. Onlamoon N, Tabprasit S, Suwanagool S, Louisirirotchanakul S, Ansari AA, Pattanapanyasat K (2005). Studies on the potential use of CD38 expression as a marker for the efficacy of anti-retroviral therapy in HIV-1-infected patients in Thailand. Virology 341(2): 238-247.
185. Sachsenberg N, Perelson AS, Yerly S, Schockmel GA, Leduc D, Hirschel B, Perrin L (1998). Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med 187(8): 1295-1303.
186. Douek DC, Betts MR, Hill BJ, Little SJ, Lempicki R, Metcalf JA, Casazza J, Yoder C, Adelsberger JW, Stevens RA, Baseler MW, Keiser P, Richman DD, Davey RT, Koup RA (2001). Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol 167(11): 6663-6668.
187. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, Sereti I, Polis MA, Davey RT, Tavel J, Falloon J, Stevens R, Lambert L, Dewar R, Schwartzentruber DJ, Anver MR, Baseler MW, Masur H, Dimitrov DS, Lane HC (2001). Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med 194(12): 1731-1741.
188. Sieg SF, Rodriguez B, Asaad R, Jiang W, Bazdar DA, Lederman MM (2005). Peripheral S-phase T cells in HIV disease have a central memory phenotype and rarely have evidence of recent T cell receptor engagement. Journal of Infectious Diseases 192(1): 62-70.
189. Picker LJ, Hagen SI, Lum R, Reed-Inderbitzin EF, Daly LM, Sylwester AW, Walker JM, Siess DC, Piatak M, Jr., Wang C, Allison DB, Maino VC, Lifson JD, Kodama T, Axthelm MK (2004). Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med 200(10): 1299-1314.
190. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS (1990). HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61(2): 213-222.
191. Ramilo O, Bell KD, Uhr JW, Vitetta ES (1993). Role of CD25+ and CD25-T cells in acute HIV infection in vitro. J Immunol 150(11): 5202-5208.
192. Sieg SF, Bazdar DA, Lederman MM (2008). S-phase entry leads to cell death in circulating T cells from HIV-infected persons. J Leukoc Biol 83(6): 1382-1387.
193. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, Larsson M, Gorelick RJ, Lifson JD, Bhardwaj N (2005). Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 115(11): 3265-3275.
194. Meier A, Altfeld M (2007). Toll-like receptor signaling in HIV-1 infection: a potential target for therapy? Expert Rev Anti Infect Ther 5(3): 323-326.
195. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR (2010). A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 467(7312): 214-217.
196. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J (2010). The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 11(11): 1005-1013.
197. Shebl FM, Yu K, Landgren O, Goedert JJ, Rabkin CS (2012). Increased levels of circulating cytokines with HIV-related immunosuppression. AIDS Res Hum Retroviruses 28(8): 809-815.
198. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG (2011). Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 203(10): 1474-1483.
199. Okoye A, Meier-Schellersheim M, Brenchley JM, Hagen SI, Walker JM, Rohankhedkar M, Lum R, Edgar JB, Planer SL, Legasse A, Sylwester AW, Piatak M, Jr., Lifson JD, Maino VC, Sodora DL, Douek DC, Axthelm MK, Grossman Z, Picker LJ (2007). Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med 204(9): 2171-2185.
200. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC (2006). Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12(12): 1365-1371.
201. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM (2008). Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One 3(4): e1915.
202. Sodora DL, Allan JS, Apetrei C, Brenchley JM, Douek DC, Else JG, Estes JD, Hahn BH, Hirsch VM, Kaur A, Kirchhoff F, Muller-Trutwin M, Pandrea I, Schmitz JE, Silvestri G (2009). Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med 15(8): 861-865.
203. Estes JD, Gordon SN, Zeng M, Chahroudi AM, Dunham RM, Staprans SI, Reilly CS, Silvestri G, Haase AT (2008). Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J Immunol 180(10): 6798-6807.
204. Meythaler M, Martinot A, Wang Z, Pryputniewicz S, Kasheta M, Ling B, Marx PA, O'Neil S, Kaur A (2009). Differential CD4+ T-lymphocyte apoptosis and bystander T-cell activation in rhesus macaques and sooty mangabeys during acute simian immunodeficiency virus infection. J Virol 83(2): 572-583.
205. Lederer S, Favre D, Walters KA, Proll S, Kanwar B, Kasakow Z, Baskin CR, Palermo R, McCune JM, Katze MG (2009). Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog 5(2): e1000296.
206. Bruel T, Dupuy S, Demoulins T, Rogez-Kreuz C, Dutrieux J, Corneau A, Cosma A, Cheynier R, Dereuddre-Bosquet N, Le Grand R, Vaslin B (2014). Plasmacytoid dendritic cell dynamics tune interferon-alfa production in SIV-infected cynomolgus macaques. PLoS Pathog 10(1): e1003915.
207. Hardy GA, Sieg S, Rodriguez B, Anthony D, Asaad R, Jiang W, Mudd J, Schacker T, Funderburg NT, Pilch-Cooper HA, Debernardo R, Rabin RL, Lederman MM, Harding CV (2013). Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One 8(2): e56527.
208. Alimonti JB, Koesters SA, Kimani J, Matu L, Wachihi C, Plummer FA, Fowke KR (2005). CD4+ T cell responses in HIV-exposed seronegative women are qualitatively distinct from those in HIV-infected women. J Infect Dis 191(1): 20-24.
209. Alimonti JB, Kimani J, Matu L, Wachihi C, Kaul R, Plummer FA, Fowke KR (2006). Characterization of CD8 T-cell responses in HIV-1-exposed seronegative commercial sex workers from Nairobi, Kenya. Immunol Cell Biol 84(5): 482-485.
210. Hardie RA, Luo M, Bruneau B, Knight E, Nagelkerke NJ, Kimani J, Wachihi C, Ngugi EN, Plummer FA (2008). Human leukocyte antigen-DQ alleles and haplotypes and their associations with resistance and susceptibility to HIV-1 infection. AIDS 22(7): 807-816.
211. Lacap PA, Huntington JD, Luo M, Nagelkerke NJ, Bielawny T, Kimani J, Wachihi C, Ngugi EN, Plummer FA (2008). Associations of human leukocyte antigen DRB with resistance or susceptibility to HIV-1 infection in the Pumwani Sex Worker Cohort. AIDS 22(9): 1029-1038.
212. MacDonald KS, Fowke KR, Kimani J, Dunand VA, Nagelkerke NJ, Ball TB, Oyugi J, Njagi E, Gaur LK, Brunham RC, Wade J, Luscher MA, Krausa P, Rowland-Jones S, Ngugi E, Bwayo JJ, Plummer FA (2000). Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect Dis 181(5): 1581-1589.
213. Ball TB, Ji H, Kimani J, McLaren P, Marlin C, Hill AV, Plummer FA (2007). Polymorphisms in IRF-1 associated with resistance to HIV-1 infection in highly exposed uninfected Kenyan sex workers. AIDS 21(9): 1091-1101.
214. McLaren PJ, Ball TB, Wachihi C, Jaoko W, Kelvin DJ, Danesh A, Kimani J, Plummer FA, Fowke KR (2010). HIV-exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV-dependent host factors. J Infect Dis 202 Suppl 3: S339-344.
215. Koning FA, van der Vorst TJ, Schuitemaker H (2005). Low levels of human immunodeficiency virus type 1 DNA in high-risk seronegative men. J Virol 79(10): 6551-6553.
216. Jennes W, Evertse D, Borget MY, Vuylsteke B, Maurice C, Nkengasong JN, Kestens L (2006). Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers. Clin Exp Immunol 143(3): 435-444.
217. Broder S (2010). The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 85(1): 1-18.
218. Kulpa DA, Chomont N (2015). HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J Virus Erad 1(2): 59-66.
219. Guerrero MLF, Rivas P, Molina M, Garcia R, De Gorgolas M (2005). Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy. Clinical Infectious Diseases 41(3): 390-394.
220. Ford N, Calmy A, Hurst S (2010). When to start antiretroviral therapy in resource-limited settings: a human rights analysis. Bmc International Health and Human Rights 10: 6.
221. Deeks SG (2000). Determinants of virological response to antiretroviral therapy: Implications for long-term strategies. Clinical Infectious Diseases 30: S177-S184.
222. Lee PK, Kieffer TL, Siliciano RF, Nettles RE (2006). HIV-1 viral load blips are of limited clinical significance. Journal of Antimicrobial Chemotherapy 57(5): 803-805.
223. Bertozzi S, Padian NS, Wegbreit J, DeMaria LM, Feldman B, Gayle H, Gold J, Grant R, Isbell MT (2006). HIV/AIDS Prevention and Treatment. Disease Control Priorities in Developing Countries, 2nd Edition: 331-369.
224. Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, Hare CB (2015). No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clinical Infectious Diseases 61(10): 1601-1603.
225. Sabin CA, Phillips AN (2009). Should HIV therapy be started at a CD4 cell count above 350 cells/mu l in asymptomatic HIV-1-infected patients? Current Opinion in Infectious Diseases 22(2): 191-197.
226. Jain V, Deeks SG (2010). When to start antiretroviral therapy. Curr HIV/AIDS Rep 7(2): 60-68.
227. Franco RA, Saag MS (2013). When to start antiretroviral therapy: as soon as possible. BMC Med 11: 147.
228. Lundgren JD, Babiker AG, Gordin FM, Borges AH, Neaton JD (2013). When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med 11: 148.
229. Group TAS, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, Ouattara E, Anzian A, Ntakpe JB, Minga A, Kouame GM, Bouhoussou F, Emieme A, Kouame A, Inwoley A, Toni TD, Ahiboh H, Kabran M, Rabe C, Sidibe B, Nzunetu G, Konan R, Gnokoro J, Gouesse P, Messou E, Dohoun L, Kamagate S, Yao A, Amon S, et al. (2015). A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 373(9): 808-822.
230. Geffen N, Aagaard P, Corbelli GM, Meulbroek M, Peavy D, Rappoport C, Schwarze S, Collins S, International Network for Strategic Initiatives in Global HIVTCAB (2015). Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 16 Suppl 1: 10-13.
231. Karim SSA (2015). Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy. New England Journal of Medicine 373(9): 875-876.
232. Lahuerta M, Ue F, Hoffman S, Elul B, Kulkarni SG, Wu YF, Nuwagaba-Biribonwoha H, Remien RH, El Sadr W, Nash D (2013). The Problem of Late ART Initiation in Sub-Saharan Africa: A Transient Aspect of Scale-up or a Long-term Phenomenon? Journal of Health Care for the Poor and Underserved 24(1): 359-383.
233. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B, Hill T, Walsh J, Fisher M, Orkin C, Ainsworth J, Bansi L, Phillips A, Leen C, Nelson M, Anderson J, Sabin C (2011). Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. British Medical Journal 343: d6016.
234. Nachega JB, Parienti JJ, Uthman OA, Gross R, Dowdy DW, Sax PE, Gallant JE, Mugavero MJ, Mills EJ, Giordano TP (2014). Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. Clinical Infectious Diseases 58(9): 1297-1307.
235. Pennings PS (2013). HIV Drug Resistance: Problems and Perspectives. Infect Dis Rep 5(Suppl 1): e5.
236. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, Furrer H, van Cutsem G, Ledergerber B, Boulle A, Swiss HIVCS, the International Epidemiologic Databases to Evaluate AiSA (2008). Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 5(7): e148.
237. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW (2014). Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 111(6): 2307-2312.
238. McKinnon LR, Kimani M, Wachihi C, Nagelkerke NJ, Muriuki FK, Kariri A, Lester RT, Gelmon L, Ball TB, Plummer FA, Kaul R, Kimani J (2010). Effect of baseline HIV disease parameters on CD4+ T cell recovery after antiretroviral therapy initiation in Kenyan women. PLoS One 5(7): e11434.
239. Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, McCune JM, Moreno S, Deeks SG (2014). HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 10(5): e1004078.
240. Serrano-Villar S, Perez-Elias MJ, Dronda F, Casado JL, Moreno A, Royuela A, Perez-Molina JA, Sainz T, Navas E, Hermida JM, Quereda C, Moreno S (2014). Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. PLoS One 9(1): e85798.
241. Boulle A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, Keiser O, Lampe FC, Giddy J, Ndirangu J, Garone D, Fox M, Ingle SM, Reiss P, Dabis F, Costagliola D, Castagna A, Ehren K, Campbell C, Gill MJ, Saag M, Justice AC, Guest J, Crane HM, Egger M, Sterne JA (2014). Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. PLoS Med 11(9): e1001718.
242. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R, Chadwick D, Martin F, Hill T, Walsh J, Post F, Fisher M, Ainsworth J, Jose S, Leen C, Nelson M, Anderson J, Sabin C, Study UKCHC (2014). Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS 28(8): 1193-1202.
243. Rosenbloom DI, Hill AL, Rabi SA, Siliciano RF, Nowak MA (2012). Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med 18(9): 1378-1385.
244. Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL (2012). Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother 56(10): 5000-5008.
245. Frentz D, Boucher CA, van de Vijver DA (2012). Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 14(1): 17-27.
246. Wainberg MA, Brenner BG (2010). Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs. Viruses 2(11): 2493-2508.
247. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, Wainberg MA (2006). HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20(9): F9-13.
248. Gupta RK, Chrystie IL, O'Shea S, Mullen JE, Kulasegaram R, Tong CY (2005). K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. AIDS 19(16): 1916-1919.
249. Wainberg MA, Brenner BG (2012). The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs. Mol Biol Int 2012(256982).
250. Marsden MD, Zack JA (2015). Double trouble: HIV latency and CTL escape. Cell Host Microbe 17(2): 141-142.
251. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF (2015). Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517(7534): 381-385.
252. Shan L, Siliciano RF (2013). From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. Bioessays 35(6): 544-552.
253. Marsden MD, Zack JA (2013). HIV/AIDS eradication. Bioorg Med Chem Lett 23(14): 4003-4010.
254. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF (2012). Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36(3): 491-501.
255. Liu C, Ma X, Liu B, Chen C, Zhang H (2015). HIV-1 functional cure: will the dream come true? BMC Med 13: 284.
256. Wilen CB, Tilton JC, Doms RW (2012). HIV: cell binding and entry. Cold Spring Harb Perspect Med 2(8).
257. Tardif MR, Tremblay MJ (2003). Presence of host ICAM-1 in human immunodeficiency virus type 1 virions increases productive infection of CD4+ T lymphocytes by favoring cytosolic delivery of viral material. J Virol 77(22): 12299-12309.
258. Didigu CA, Doms RW (2012). Novel approaches to inhibit HIV entry. Viruses 4(2): 309-324.
259. Lifson JD, Engleman EG (1989). Role of CD4 in normal immunity and HIV infection. Immunol Rev 109(93-117.
260. Doores KJ (2015). The HIV glycan shield as a target for broadly neutralizing antibodies. FEBS J 282(24): 4679-4691.
261. Dotsey EY, Gorlani A, Ingale S, Achenbach CJ, Forthal DN, Felgner PL, Gach JS (2015). A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens. PLoS One 10(5): e0125581.
262. Vigerust DJ (2011). Protein glycosylation in infectious disease pathobiology and treatment. Central European Journal of Biology 6(5): 802-816.
263. Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB (2013). A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLoS One 8(8): e72054.
264. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, Swanstrom R (2002). Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. Journal of Virology 76(8): 3852-3864.
265. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG (1998). The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393(6686): 705-711.
266. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393(6686): 648-659.
267. Garcia-Perez J, Staropoli I, Azoulay S, Heinrich JT, Cascajero A, Colin P, Lortat-Jacob H, Arenzana-Seisdedos F, Alcami J, Kellenberger E, Lagane B (2015). A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity. Retrovirology 12: 50.
268. Doms RW, Moore JP (2000). HIV-1 membrane fusion: targets of opportunity. J Cell Biol 151(2): F9-14.
269. Marmor M, Hertzmark K, Thomas SM, Halkitis PN, Vogler M (2006). Resistance to HIV infection. J Urban Health 83(1): 5-17.
270. Berger EA, Doms RW, Fenyo EM, Korber BTM, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA (1998). A new classification for HIV-1. Nature 391(6664): 240-240.
271. Grivel JC, Shattock RJ, Margolis LB (2011). Selective transmission of R5 HIV-1 variants: where is the gatekeeper? Journal of Translational Medicine 9 Suppl 1:S6.
272. Lehmann MJ, Sherer NM, Marks CB, Pypaert M, Mothes W (2005). Actin-and myosin-driven movement of viruses along filopodia precedes their entry into cells. J Cell Biol 170(2): 317-325.
273. Coyne CB, Bergelson JM (2006). Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124(1): 119-131.
274. Sherer NM, Jin J, Mothes W (2010). Directional spread of surface-associated retroviruses regulated by differential virus-cell interactions. J Virol 84(7): 3248-3258.
275. Mothes W, Sherer NM, Jin J, Zhong P (2010). Virus cell-to-cell transmission. J Virol 84(17): 8360-8368.
276. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB (2009). HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137(3): 433-444.
277. Gach JS, Leaman DP, Zwick MB (2011). Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. Curr Top Med Chem 11(24): 2997-3021.
278. Melikyan GB (2008). Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology 5: 111.
279. Martin N, Welsch S, Jolly C, Briggs JA, Vaux D, Sattentau QJ (2010). Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol 84(7): 3516-3527.
280. Abela IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, Rusert P, Trkola A (2012). Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog 8(4): e1002634.
281. Jolly C (2011). Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction factors. Virology 411(2): 251-259.
282. Chen P, Hubner W, Spinelli MA, Chen BK (2007). Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol 81(22): 12582-12595.
283. Mazurov D, Ilinskaya A, Heidecker G, Lloyd P, Derse D (2010). Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. PLoS Pathog 6(2): e1000788.
284. Felts RL, Narayan K, Estes JD, Shi D, Trubey CM, Fu J, Hartnell LM, Ruthel GT, Schneider DK, Nagashima K, Bess JW, Jr., Bavari S, Lowekamp BC, Bliss D, Lifson JD, Subramaniam S (2010). 3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A 107(30): 13336-13341.
285. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y (2000). DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100(5): 587-597.
286. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ (2003). Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 300(5623): 1295-1297.
287. Turville SG, Cameron PU, Handley A, Lin G, Pohlmann S, Doms RW, Cunningham AL (2002). Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol 3(10): 975-983.
288. Hubner W, McNerney GP, Chen P, Dale BM, Gordon RE, Chuang FY, Li XD, Asmuth DM, Huser T, Chen BK (2009). Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science 323(5922): 1743-1747.